ACTIFED W/ CODEINE Drug Patent Profile

Which patents cover Actifed W/ Codeine, and when can generic versions of Actifed W/ Codeine launch?

Actifed W/ Codeine is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in ACTIFED W/ CODEINE is codeine phosphate; pseudoephedrine hydrochloride; triprolidine hydrochloride. There are nineteen drug master file entries for this compound. Additional details are available on the codeine phosphate; pseudoephedrine hydrochloride; triprolidine hydrochloride profile page.

Summary for ACTIFED W/ CODEINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ACTIFED W/ CODEINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ACTIFED W/ CODEINE	codeine phosphate; pseudoephedrine hydrochloride; triprolidine hydrochloride	SYRUP;ORAL	012575-003	Apr 4, 1984		DISCN	No	No

ACTIFED W/ CODEINE: PATENT LANDSCAPE AND INVESTMENT FUNDAMENTALS

Last updated: February 19, 2026

Summary: Actifed w/ Codeine, a combination antitussive and antihistamine, faces a mature patent landscape. While core composition patents have expired, formulation and manufacturing process patents may offer limited, short-term exclusivity. Market competition is high, driven by generic entrants and alternative treatments. Investment fundamentals are contingent on strategic market positioning, lifecycle management opportunities, and potential for new indications or delivery systems.

MARKET DYNAMICS AND PATENT OVERVIEW

What is the current patent status of Actifed w/ Codeine?

The foundational composition of matter patents for Actifed w/ Codeine, comprising guaifenesin, pseudoephedrine hydrochloride, and codeine phosphate, have expired. The primary active pharmaceutical ingredients (APIs) – guaifenesin, pseudoephedrine, and codeine – are all available as off-patent substances.

The patent protection landscape for Actifed w/ Codeine primarily revolves around:

• Formulation Patents: These patents may cover specific ratios of APIs, excipients, or novel delivery systems designed to improve stability, bioavailability, or patient compliance.
  • Examples include patents related to sustained-release formulations or specific tablet/syrup compositions.
• Manufacturing Process Patents: These patents protect unique methods of synthesizing or producing the drug product.
  • These can offer a competitive advantage by reducing production costs or improving purity, but their lifespan is typically shorter than composition patents.
• Method of Use Patents: While less common for established combination drugs, patents might exist for novel therapeutic uses of the combination, although this is unlikely for a product with decades of clinical use.

Patent Expiry Dates for Core APIs:

• Codeine: The earliest patents related to codeine synthesis and its pharmacological properties expired in the early to mid-20th century.
• Pseudoephedrine: Patents covering its synthesis and use also expired decades ago.
• Guaifenesin: Similar to the other APIs, its patent protection has long lapsed.

The absence of robust, long-term composition of matter patent protection for Actifed w/ Codeine means that generic manufacturers have had significant opportunities to enter the market upon the expiry of any peripheral formulation or process patents.

What is the competitive landscape for Actifed w/ Codeine?

The market for Actifed w/ Codeine is characterized by intense competition from multiple sources:

• Generic Equivalents: The availability of off-patent APIs allows numerous pharmaceutical companies to manufacture and market generic versions of Actifed w/ Codeine. These products typically compete on price, making it challenging for branded products to maintain significant market share without strong differentiation.
• Over-the-Counter (OTC) Cough and Cold Preparations: Actifed w/ Codeine, while historically available by prescription in some formulations due to codeine content, competes with a vast array of OTC cough and cold remedies. These include single-API products (e.g., dextromethorphan, guaifenesin, pseudoephedrine alone) and other combination products.
• Alternative Treatment Modalities:
  • Non-opioid Antitussives: Drugs like dextromethorphan and levodropropizine are widely used and do not carry the regulatory and addiction concerns associated with codeine.
  • Newer Antihistamines: The development of second and third-generation antihistamines with improved safety profiles (e.g., less sedation) and efficacy offers alternatives to older first-generation antihistamines like triprolidine or diphenhydramine that might be found in some Actifed formulations.
  • Specialty Cough Treatments: Emerging treatments focusing on specific cough mechanisms or refractory cough conditions also present competition.

Key Competitive Factors:

• Price: Generic products offer a significant price advantage.
• Regulatory Status: Codeine's controlled substance status in many regions impacts its accessibility and prescribing patterns, favoring non-codeine alternatives.
• Safety and Side Effect Profile: Newer generations of antihistamines and antitussives often have more favorable side effect profiles (e.g., reduced drowsiness).
• Marketing and Brand Recognition: While Actifed has brand recognition, it is often countered by extensive marketing of both generic and alternative OTC brands.

What are the regulatory considerations impacting Actifed w/ Codeine?

Regulatory scrutiny significantly shapes the market for Actifed w/ Codeine, primarily due to the presence of codeine:

• Controlled Substance Status: Codeine is a Schedule V controlled substance in the United States and subject to similar regulations in many other countries. This requires:
  • Prescription-only status.
  • Strict dispensing and record-keeping requirements for pharmacies.
  • Potential state-specific restrictions on refills or quantities.
  • Increased diversion risk and public health concerns related to opioid misuse.
• DEA Regulations (U.S.): The Drug Enforcement Administration (DEA) monitors and regulates the manufacturing, distribution, and dispensing of codeine-containing products. Quotas and reporting are in place.
• International Regulations: Varying international classifications of codeine as a narcotic or psychotropic substance lead to different access levels and prescription requirements across global markets.
• FDA Monograph Review: For non-prescription cough and cold products, the FDA's Over-the-Counter (OTC) Drug Monograph system sets conditions under which certain drugs are generally recognized as safe and effective (GRASE). While Actifed w/ Codeine as a prescription product operates outside some aspects of direct monograph review for its specific combination, the underlying ingredients are subject to safety and efficacy assessments. Regulatory shifts concerning the appropriateness of codeine in combination cold products could impact its long-term market viability.
• Marketing Restrictions: Regulators may impose restrictions on marketing claims for products containing controlled substances, especially concerning their safety and efficacy for general cough and cold symptoms.

These regulatory factors contribute to a declining preference for codeine-containing cough suppressants in favor of safer, non-opioid alternatives, particularly in the OTC space and for less severe cough symptoms.

INVESTMENT FUNDAMENTALS AND STRATEGIC OPPORTUNITIES

What is the historical market performance of Actifed w/ Codeine?

Historical market performance data for Actifed w/ Codeine as a specific branded product is challenging to isolate due to its long presence and the widespread adoption of generic versions. However, general trends for prescription combination cough and cold products containing codeine indicate a decline in market share and revenue over the past two decades.

Key Indicators of Historical Performance:

• Market Share Erosion: The introduction of generics and the shift towards OTC alternatives have significantly reduced the market share of branded, prescription codeine-containing cough suppressants.
• Declining Prescription Volumes: Regulatory pressures, physician preference for non-opioid alternatives, and patient demand for more convenient OTC options have led to a decrease in prescription volumes for such products.
• Price Pressures: Competition from generics forces down average selling prices (ASPs), impacting overall revenue even if unit volumes remain stable in certain niche segments.
• Impact of Opioid Crisis: The heightened awareness and concern surrounding the opioid epidemic have led to a re-evaluation of codeine's role in widespread symptomatic treatment, further contributing to declining use.

While precise revenue figures for the branded Actifed w/ Codeine are proprietary and vary by manufacturer and region, the overall trend for this class of pharmaceuticals has been downward. Companies relying on this product for significant revenue have historically needed to diversify their portfolios.

What are the potential risks and challenges for investing in Actifed w/ Codeine?

Investing in Actifed w/ Codeine, particularly as a branded product, presents several significant risks and challenges:

• Patent Expiry and Generic Competition: As detailed previously, the lack of robust, long-term patent protection allows for widespread generic entry, driving down prices and market share for branded versions.
• Regulatory Hurdles and Scrutiny: The controlled substance status of codeine makes it a target for increased regulatory oversight, potential restrictions, and public health concerns. This can lead to evolving prescribing guidelines and a shift towards non-opioid alternatives.
• Declining Physician and Patient Preference: Healthcare providers are increasingly opting for non-opioid antitussives and more sedating antihistamines due to safety concerns, addiction potential, and the availability of perceived safer alternatives. Patients also seek more convenient OTC options.
• Market Saturation: The cough and cold market is highly saturated with a wide array of products, making it difficult for any single product, especially a prescription-only one with controlled substance status, to gain significant traction or command premium pricing.
• Stagnant or Declining Demand: The primary indications for Actifed w/ Codeine (cough, congestion) are often treated with non-prescription alternatives, limiting the growth potential of this prescription product.
• Product Lifecycle Stage: Actifed w/ Codeine is a mature product. Without significant innovation or new indications, its lifecycle is likely characterized by declining sales and market relevance.
• Manufacturing and Supply Chain Complexity: Sourcing and managing controlled substances like codeine can involve more complex supply chain logistics, compliance requirements, and higher associated costs compared to non-controlled APIs.

What are the potential strategic opportunities or mitigation strategies?

Despite the challenges, certain strategic avenues might exist for entities involved with Actifed w/ Codeine, focusing on niche markets, lifecycle extension, or leveraging existing infrastructure.

• Niche Market Penetration:
  • Specific Prescriber Segments: Targeting physician groups or specialized clinics where codeine-containing antitussives are still preferred for specific, severe cough symptoms or post-operative care.
  • Geographic Markets with Favorable Regulations: Focusing on regions or countries where codeine's regulatory status is less restrictive or where physician preference for this combination remains stronger.
• Lifecycle Management and Formulation Innovation:
  • Novel Delivery Systems: Exploring new formulations that improve patient compliance, reduce dosing frequency, or enhance the pharmacokinetic profile. This could include extended-release versions or novel combination ratios, provided they can be adequately patented.
  • Combination with Newer APIs: Investigating potential combinations with newer, patent-protected APIs from different therapeutic classes that could offer synergistic benefits or address unmet needs, though this is a complex undertaking for an established product.
• Cost Optimization and Efficient Manufacturing:
  • Lean Manufacturing Processes: Implementing highly efficient manufacturing processes to reduce cost of goods sold (COGS), thereby enabling competitive pricing against generics and maintaining profitability in a declining market.
  • Optimized Supply Chain Management: Streamlining the supply chain for codeine and other APIs to ensure cost-effectiveness and compliance.
• Geographic Expansion (with Caution):
  • Emerging Markets: Evaluating emerging markets where prescription patterns might differ and where regulatory frameworks are less stringent, presenting an opportunity for established products. This requires thorough due diligence on local regulatory requirements and market acceptance.
• Portfolio Diversification (for companies):
  • Leveraging Infrastructure: For manufacturers, leveraging existing production lines and distribution networks for Actifed w/ Codeine to produce other combination products or generics in the cough and cold category, rather than solely focusing on the branded product.
  • Acquisition of Complementary Assets: Companies might consider acquiring assets or products that complement Actifed w/ Codeine's therapeutic area but offer better growth prospects or patent protection.

These strategies require a clear understanding of market dynamics, regulatory landscapes, and a pragmatic assessment of the potential return on investment relative to the inherent risks.

KEY TAKEAWAYS

• Expired Core Patents: Actifed w/ Codeine's primary APIs (guaifenesin, pseudoephedrine, codeine) are off-patent, allowing for widespread generic competition.
• Limited Exclusivity: Any remaining patent protection is likely confined to specific formulations or manufacturing processes, offering short-term or niche advantages.
• Intense Market Competition: The product faces competition from generics, a broad range of OTC cough and cold remedies, and newer, potentially safer alternative treatments.
• Regulatory Headwinds: Codeine's controlled substance status leads to significant regulatory oversight, prescription requirements, and increasing public health concerns regarding opioid misuse, driving a shift towards non-opioid alternatives.
• Declining Market Preference: Physician and patient preference is trending away from codeine-containing products due to safety profiles, addiction risks, and the availability of alternatives.
• Investment Focus: Investment opportunities are contingent on identifying niche markets, successful lifecycle management through formulation innovation, cost optimization, or strategic geographic expansion.

FREQUENTLY ASKED QUESTIONS

1. Can Actifed w/ Codeine be reintroduced as an over-the-counter (OTC) product?

No, Actifed w/ Codeine, due to its codeine content, is classified as a controlled substance and is generally prescription-only. Regulatory bodies like the FDA have strict guidelines for OTC status, and controlled substances typically do not qualify for OTC availability due to safety, diversion, and misuse concerns.

2. What are the primary therapeutic benefits of Actifed w/ Codeine?

Actifed w/ Codeine combines an antitussive (codeine) to suppress cough reflexes with an antihistamine (typically triprolidine or diphenhydramine) and a decongestant (pseudoephedrine) to relieve nasal congestion. Its primary benefit is symptom relief for cough, cold, and upper respiratory congestion.

3. How has the opioid crisis impacted the market for Actifed w/ Codeine?

The opioid crisis has led to increased scrutiny of all codeine-containing products. This has resulted in stricter prescribing regulations, reduced physician willingness to prescribe codeine for common ailments, and a push from public health officials and regulatory agencies towards non-opioid alternatives for cough and pain management.

4. Are there any significant formulation innovations currently protecting Actifed w/ Codeine?

While specific proprietary formulations might have had patent protection in the past, the core composition is off-patent. Any current or recent patent protection would likely relate to specific excipient combinations, release profiles, or unique manufacturing methods, rather than the fundamental API combination itself. Such patents are typically shorter-lived than composition-of-matter patents.

5. What is the typical lifespan of a patent for a pharmaceutical formulation?

Patents for pharmaceutical formulations typically have a term of 20 years from the filing date. However, this can be extended through mechanisms like Patent Term Extension (PTE) to compensate for regulatory review delays. For older drugs like Actifed w/ Codeine, any formulation patents would have been filed many years ago, and their original or extended terms have likely expired or are nearing expiry.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Controlled Substances Act. Retrieved from [FDA Website - General Information on Controlled Substances] [2] Drug Enforcement Administration. (n.d.). Schedules of Controlled Substances. Retrieved from [DEA Website - Schedules] [3] Weisberg, R. B., & Baker, S. R. (2013). The Over-the-Counter Monograph System: A Historical Perspective and Future Outlook. Drug Information Journal, 47(3), 281–290. [4] National Institute on Drug Abuse. (2024). Opioid Overdose Crisis. Retrieved from [NIDA Website - Opioid Crisis Information]